Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Current Deferred Revenue: 2017-2025

Historic Current Deferred Revenue for Assembly Biosciences (ASMB) over the last 7 years, with Sep 2025 value amounting to $42.4 million.

  • Assembly Biosciences' Current Deferred Revenue fell 34.96% to $42.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year decrease of 34.96%. This contributed to the annual value of $37.6 million for FY2024, which is 56.40% down from last year.
  • Latest data reveals that Assembly Biosciences reported Current Deferred Revenue of $42.4 million as of Q3 2025, which was up 3.53% from $40.9 million recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' Current Deferred Revenue peaked at $86.3 million during Q4 2023, and registered a low of $2.7 million during Q3 2021.
  • Over the past 3 years, Assembly Biosciences' median Current Deferred Revenue value was $53.7 million (recorded in 2024), while the average stood at $58.2 million.
  • In the last 5 years, Assembly Biosciences' Current Deferred Revenue tumbled by 75.06% in 2021 and then spiked by 3,057.48% in 2023.
  • Over the past 5 years, Assembly Biosciences' Current Deferred Revenue (Quarterly) stood at $2.7 million in 2021, then remained steady at $2.7 million in 2022, then soared by 3,057.48% to $86.3 million in 2023, then crashed by 56.40% to $37.6 million in 2024, then crashed by 34.96% to $42.4 million in 2025.
  • Its Current Deferred Revenue was $42.4 million in Q3 2025, compared to $40.9 million in Q2 2025 and $40.8 million in Q1 2025.